Merck KGaA (OTCMKTS:MKKGY) Receives Average Rating of “Hold” from Analysts

Merck KGaA (OTCMKTS:MKKGY – Get Free Report) has earned an average recommendation of “Hold” from the six research firms that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a hold recommendation.

A number of brokerages recently commented on MKKGY. UBS Group cut Merck KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 20th. HSBC raised Merck KGaA to a “hold” rating in a research note on Monday, July 6th. Finally, Zacks Research lowered Merck KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th.

Get Our Latest Research Report on Merck KGaA

Merck KGaA Trading Up 0.7%

OTCMKTS:MKKGY opened at $30.86 on Tuesday. The business’s 50-day simple moving average is $31.81 and its 200 day simple moving average is $29.68. The stock has a market cap of $19.94 billion, a price-to-earnings ratio of 15.91, a price-to-earnings-growth ratio of 2.92 and a beta of 0.96. Merck KGaA has a one year low of $23.73 and a one year high of $34.19. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.09 and a current ratio of 1.69.

About Merck KGaA

(Get Free Report)

Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest pharmaceutical and chemical businesses. Merck KGaA operates independently from the U.S.-based Merck & Co, Inc, which uses the name MSD in markets outside the United States and Canada.

The company operates through three primary business sectors: Life Science, Healthcare and Electronics. Its Life Science business supplies laboratory products, research tools, bioprocessing equipment and services used by academic institutions, pharmaceutical manufacturers and other industrial customers.

Further Reading

Analyst Recommendations for Merck KGaA (OTCMKTS:MKKGY)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.